Table 1 Baseline characteristics of 37 patients with hepatocellular carcinoma treated with ramucirumab
Demographics/characteristics | All patients (n = 37) |
|---|---|
Sex, male | 31 (83.8%) |
Age, ≥ 73 years old | 19 (51.4%) |
HBs Ag-positive | 8 (21.6%) |
 HBV DNA below detection limit due to nucleic acid | 7 (18.9%) |
HCV Ab-positive | 14 (37.8%) |
 Achieved SVR | 11 (29.7%) |
Alcohol abuse | 6 (16.2%) |
Smoking history | 23 (62.2%) |
Body weight, < 60 kg | 18 (48.6%) |
Hypertension | 24 (64.9%) |
Diabetes mellitus | 12 (32.4%) |
Hyperlipidemia | 11 (29.7%) |
Liver cirrhosis | 12 (32.4%) |
ECOG-PS, ≤ 1 | 36 (97.3%) |
Child–Pugh score | |
 5 | 17 (45.9%) |
 6 | 13 (35.1%) |
  ≥ 7 | 7 (18.9%) |
Number of intrahepatic lesions, ≥ 8 | 21 (56.8%) |
Maximum size of intrahepatic lesions, > 50 mm | 21 (56.8%) |
Intrahepatic tumor occupation, ≥ 50% | 3 (8.1%) |
MVI | 8 (21.6%) |
EHM | 18 (48.6%) |
BCLC stage C | 21 (56.8%) |
Tumor differentiation | |
 Well differentiated | 1 (2.7%) |
 Moderately differentiated | 21 (56.8%) |
 Poorly differentiated | 4 (10.8%) |
Pre-treatment before administration of systemic therapy | 32 (86.5%) |
 Resection | 10 (27.0%) |
 Local ablation | 13 (35.1%) |
 TACE | 28 (75.7%) |